Archive for January 23rd, 2022

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

23-Jan-2022 Intellasia | PR Newswire Asia | 5:35 PM

-- Approximately 80% of 180 patients with recurrent glioblastoma (rGBM) in the Phase III clinical trial are expected to be randomized and enrolled by the [...] » More

Sanya Welcomes Travelers this Spring Festival with an Exciting Lineup of Cultural Activities

Sanya Welcomes Travelers this Spring Festival with an Exciting Lineup of Cultural Activities

23-Jan-2022 Intellasia | PR Newswire Asia | 8:00 AM

SANYA, China, Jan. 23, 2022 /PRNewswire/ -- As the world prepares to ring in the Year of the Tiger, the Sanya Tourism Promotion Board [...] » More